Transcription factors play a key role in the development and differentiation of specific lineages from multipotential progenitors. This theme has been studied extensively for some hematopoietic lineages, notably erythroid and lymphoid cells, but only recently have some of the major regulators of monocytic cells been identified (25, 58) . Identification of these regulators and determining the mechanism of how they activate their target genes not only are important for understanding normal development of monocytes and macrophages, but recent studies have implicated many of these transcription factors in the pathogenesis of the most common form of adult acute leukemia, in which the differentiation of monocytic cells is blocked (33) .
An example of a transcription factor which plays an important role in normal monocytic gene expression and in acute myelogenous leukemia (AML) is AML1. AML1 is a member of the core binding factor (CBF) or polyomavirus enhancerbinding protein 2 (PEBP2) family of transcription factors. The members of the CBF family consist of heterodimers between DNA-binding ␣ subunits and a ␤ subunit (CBF␤) which does not bind DNA directly but which enhances the binding of the ␣ subunit (49, 73) . Multiple ␣-subunit genes, including CBFA1, AML1 (CBFA2), and CBFA3, as well as alternatively spliced isoforms of the ␣ and ␤ subunits, have been detected (31, 39, 49, 65, 68) . In particular, a short form (AML1A) and a long form (AML1B) of AML1 have been described, and it is the long form which appears to include the transactivation function (35, 39, 65, 68) . All of the CBF␣ proteins contain a Runt domain, which is similar to the protein product of the Drosophila pair-rule gene runt, which encodes an early-acting segmentation protein that regulates the expression of other segmentation genes (22, 23) . AML1 was identified by studying one of the most frequent chromosomal translocations found in AML, t(8;21)(q22;q22) (11, 34, 38, 40, 47) . In this case, the 5Ј part of the AML1 gene, including the runt domain but lacking the transactivation domain, is fused to almost the entire ETO gene on chromosome 8. Recent studies have indicated that this AML1/ETO fusion protein can act as a dominant negative inhibitor of AML1 transactivation function (12, 35, 65) . The expression of some of the normal AML1 gene targets which play a key role in monocytic differentiation might be adversely affected by AML1/ETO, and these include granulocyte mac-rophage colony-stimulating factor (GM-CSF) (12, 65) , interleukin-3 (IL-3) (6), the macrophage colony-stimulating factor (M-CSF) receptor (79) , and myeloperoxidase (45) . AML1 fusion proteins, including AML1/MDS1, AML1/EAP, AML1/ Evi-1, and TEL/AML1, are also involved in other forms of leukemia (15, 36, 46, 47, 53) . The ␤ subunit of CBF, CBF␤, is also involved in a chromosomal inversion, inv(16)(p13;q22), which is associated with FAB M4eo AML (32) . Therefore, each of the two chains of the CBF heterodimer is directly implicated in the pathogenesis of AML.
The CCAAT enhancer-binding proteins (C/EBP) represent a family of transcription factors which have been suggested to play a role in monocytic development. C/EBP␣ was the firstidentified member of one family of basic region-leucine zipper (bZIP) DNA-binding proteins (21, 27, 28) . The basic region is highly positively charged and directly interacts with DNA. The leucine zipper domain forms an ␣-helical coil and is directly involved in homo-and heterodimerization. C/EBP␣, C/EBP␤, and C/EBP␦ are strongly similar in their C-terminal basic region and leucine zipper domains and diverge in their N-terminal transactivation domains (7, 43, 76, 77) . Previous studies have hinted at a role for C/EBP in myeloid development and differentiation. The chicken homolog of C/EBP␤, NF-M, is specifically expressed in the myeloid cell lineage within the hematopoietic system (5, 16, 24, 44, 63) . NF-M binds to critical promoter regions of the chicken myelomonocytic growth factor (cMGF), which is distantly related to the mammalian hematopoietic growth factors G-CSF and IL-6. In mammals, C/EBP␤ (which is identical to human NF-IL6 [1] ) can bind to sites in promoters for the inflammatory cytokines IL-1␤, IL-6, tumor necrosis factor alpha, and G-CSF and macrophage lysozyme (42, 51, 69) . Mice with targeted disruption of the C/EBP␤ gene have shown a lymphoproliferative disorder with overexpression of IL-6 and defective macrophage activation with abnormal bacterial killing and tumor cytotoxicity (57, 67) . However, macrophage production and differentiation are apparently not blocked in C/EBP␤ Ϫ/Ϫ mice. While the C/EBP are expressed in a number of different tissues, studies to date have suggested that their expression may be limited in the hematopoietic system to myeloid (monocytic and granulocytic) cells. It has been shown that C/EBP are specifically expressed in human myelomonocytic cell lines and not in human erythroid cell, B-cell, and T-cell lines (56) , in keeping with the myeloid cell-specific expression previously noted for avian C/EBP (16, 24, 44, 63) . This indicates the possible importance of C/EBP␣ during myelomonocytic cell differentiation. In contrast to liver cells and adipocytes, in myeloid cells, C/EBP␣ is highly expressed in unstimulated and undifferentiated cells (42, 56) . When cells were treated with differentiation or activation reagents, such as IL-6, lipopolysaccharide, or G-CSF, C/EBP␤ (and C/EBP␦) expression rapidly increased and C/EBP␣ gradually decreased (42, 56) . In sum, these studies suggest the possibility that C/EBP␣ is more important for directing the commitment of multipotential hematopoietic stem cells to differentiate toward the myeloid cell lineage, while C/EBP␤ is more important for the functional activation of differentiated myeloid cells, such as macrophages, and studies of myeloid development in C/EBP␣ and C/EBP␤ knockout mice will be helpful in confirming this hypothesis. However, the key targets of the C/EBP in mammalian monocytic development and their possible role in leukemia have not been elucidated.
One potential key target for monocytic transcriptional regulators is M-CSF (CSF-1), which is involved in the differentiation, proliferation, and survival of cells of the monocytic lineage (59, 62) . The M-CSF receptor is encoded by the c-fms proto-oncogene, a cell surface tyrosine kinase (TK) receptor (59) . Normal expression of the M-CSF receptor is restricted to two tissues; monocytes and placental trophoblasts, in which it is regulated by two different promoters (52, 70) . We and others have demonstrated previously that transcriptional regulation is involved in the monocyte-specific expression of the human M-CSF receptor (20, 37, 52, 79, 80) . A small region of DNA encompassing the monocytic transcription initiation sites (bp Ϫ85 to ϩ71) of the human receptor gene shows tissue-specific promoter activity in transient transfection experiments (79) . Several transcription factors have been shown to specifically bind to the human M-CSF receptor promoter in this small region to critically regulate its expression (79, 80) . One factor is PU.1, a B-cell-and myeloid cell-specific factor encoded by the Ets family Spi-1 oncogene (26, 41) . PU.1 regulates many myeloid cell-specific genes, including the G-CSF receptor and GM-CSF receptors (19, 61) , and is essential for myeloid development (55, 71) . PU.1 interacts with the human M-CSF receptor promoter at bp Ϫ54 to Ϫ29 (80). We recently identified AML1 as a second factor which interacts with the M-CSF receptor promoter at bp Ϫ75 to Ϫ59, therefore showing that the AML1/CBF␤ heterodimer regulates the expression of a critical receptor for myeloid cell lineage differentiation (79) .
Besides PU.1 and AML1, a third monocyte-enriched factor, Mono A, interacts with the M-CSF receptor promoter at bp Ϫ87 to Ϫ73, just upstream of the AML1 site (Fig. 1A) , and is important for monocyte-specific M-CSF receptor promoter activity. Significantly, the promoter fragment containing only the Mono A-and AML1-binding sites can function as a monocytespecific enhancer element (79) . Here, we demonstrate that Mono A is identical to C/EBP. In addition, we demonstrate physical interaction and synergy between these two factors resulting in stimulation of M-CSF receptor promoter activity.
MATERIALS AND METHODS
Cell culture. Human Mono Mac 6 cells were propagated as described elsewhere (81) . African green monkey kidney fibroblast-like CV-1 cells (ATCC CCL 70) and COS-7 cells, which were established from CV-1 cells after transformation with an origin-defective mutant of simian virus 40 which produces wild-type large-T antigen (ATCC CRL 1651), were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco) with 2 mM L-glutamine.
Nuclear extracts. COS-7 cells were transfected by Ca 3 (PO 4 ) 2 precipitation with 20 g of either the C/EBP␣ expression plasmid, pMSV/EBP␣; the C/EBP␤ expression plasmid, pMSV/EBP␤; or the C/EBP␦ expression plasmid, pMSV/ EBP␦ (7). Nuclear proteins were harvested 72 h after transfection as described elsewhere (2) . Nuclear extracts from Mono Mac 6 cells were prepared by the method described by Dignam et al. (9) in the presence of 1 g of proteinase inhibitors leupeptin, pepstatin A, chymostatin, antipain, aprotinin, and trypsin inhibitor per ml. Nuclear protein concentrations were assayed by the Bradford method.
EMSA.
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P-labeled double-stranded oligonucleotides for electrophoretic mobility shift assays (EMSA) were prepared as previously described (79) . One oligonucleotide probe was the human M-CSF receptor promoter Ϫ88 to Ϫ73 region; the other probe was 5Ј-TGCAGATTGCGCAATCTGCA-3Ј, containing a C/EBP binding site (21) . DNA binding conditions were as previously described (79) . The reaction mixtures were electrophoresed at 10 V/cm on a 6% polyacrylamide gel (bisacrylamide-acrylamide, 1:29) in 0.5ϫ TBE (45 mM Tris-borate, 45 mM boric acid, 1 mM EDTA) at 4ЊC. The oligonucleotide 5Ј-TGCAGAgactagtcTCTGCA-3Ј (mutations in lowercase) was used as a C/EBP-binding mutant oligonucleotide. For antibody supershift experiments, 1 l of an antiserum raised against either the carboxyl-terminal four-fifths of murine C/EBP␣, the carboxylterminal 18 amino acids of murine C/EBP␤, or full-length murine C/EBP␦ was added to the reaction mixture (7) . Each C/EBP antiserum reacts specifically with both its murine and its human gene products and not with the other two C/EBP proteins (data not shown); for example, the C/EBP␣ antiserum reacts with murine and human C/EBP␣ but not with C/EBP␤ or C/EBP␦. As a control, 1 l of a rabbit antiserum raised against the transcription factor Oct-1 (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.) was used instead.
Plasmid constructions. The wild-type M-CSF receptor promoter-luciferase constructs p540M-CSF-R-luc and pM-CSF-R-luc, containing bp Ϫ416 to ϩ124 and bp Ϫ416 to ϩ71 of the human M-CSF receptor promoter, respectively, were described previously (80) . The mutated constructs pM-CSF-R(mA)-luc and pM-CSF-R(mB)-luc changed the sequence at bp Ϫ86 to Ϫ79 from AGATTTCC to GGTACCAT and at bp Ϫ71 to Ϫ62 from GTGGTTGCCT to CTAAGGTACC, respectively ( Fig. 1A) (79) . To construct pM-CSF-R(dAB)-luc, two DNA fragments were generated by PCR, with the plasmid p540M-CSF-R-luc as a template. Primer A (5Ј-CGGGATCCAGATATGCATTACTTTGGAGATTCCA AGG-3Ј) was used with primer B (5Ј-GGGGTACCTGGGTCTTTAAGAA G-3Ј) to generate PCR fragment 1. Primer C (5Ј-GGGGTACCCCTCGGTGG GGAAGTGGCA-3Ј) was used with primer D (5Ј-GGGGTACCTGCCTAG CTAAAAGG-3Ј) to generate PCR fragment 2. PCR fragment 1 was digested with BamHI and KpnI. PCR fragment 2 was digested with KpnI and SacI. Digested PCR fragments 1 and 2 were ligated with BamHI-and SacI-digested vector pXP2 to construct pM-CSF-R(dAB)-luc. pM-CSF-R(dAB)-luc lacks bp Ϫ86 to Ϫ62 of the wild-type promoter, and therefore deletes both C/EBP␣-and AML1-binding sites (Fig. 1A) . To construct pM-CSF-R(I5)-luc and pM-CSF-R(I10)-luc, three DNA fragments were generated by PCR with the plasmid p540M-CSF-R-luc as a template. Primer A (5Ј-CGGGATCCAGATATGCAT TACTTTGGAGATTCCAAGG-3Ј) was used with primer E (5Ј-GGGGTAC CAGTTTGGAAATCTTGG-3Ј) and primer F (5Ј-GGGGTACCTTAGAGTT TGGAAATCTTGGG-3Ј) to generate PCR fragments 3 and 4, respectively. Primer C (5Ј-GGGGTACCCCTCGGTGGGGAAGTGGCA-3Ј) was used with primer G (5Ј-GGGGTACCTGTGGTTGCCTTGCC-3Ј) to generate PCR fragment 5. PCR fragments 3 and 4 were digested with BamHI and KpnI. PCR VOL. 16, 1996 C/EBP AND AML1 SYNERGY ACTIVATES THE 1A) . pGEX-C/EBPbZIP was constructed by subcloning the human C/EBP␣ bZIP region (68a) in frame with the glutathione S-transferase (GST) moiety in pGEX-2TK (Fig. 1B) . pGEX-AML1runt contains the entire AML1 runt domain in frame with the GST moiety in the pGEX-2TK vector and was constructed by using PCR to amplify the entire runt domain with primer H (5Ј-CGCGGATCCGGCGAGCTGGT GC-3Ј) and primer I (5Ј-CCGATGCGGCCGCGAATTCTGCCGATGTCTTC GAT-3Ј) with template pCMV5-AML1B (35) , by digesting with BamHI and EcoRI, and by ligating into BamHI-and EcoRI-digested pGEX-2TK (Fig. 1B) . pGEX-CBF␤ was constructed by inserting the coding region of CBF␤ cDNA into pGEX-2T (30) . The sequences of these constructs were confirmed by the dideoxy chain termination method. Transient transfections. Mono Mac 6 cells were transfected by electroporation in RPMI 1640 medium at 960 F and 230 V. Cells were harvested 5 h posttransfection in 0.5 ml of lysis buffer, and luciferase assays were performed as previously described (50) . CV-1 cells were transfected by the Ca 3 (PO 4 ) 2 precipitation method with 10 g of the M-CSF receptor promoter luciferase constructs in the presence or absence of other transcription factor expression constructs, with salmon sperm DNA as carrier, to a total of 25 g of DNA per ml of Ca 3 (PO 4 ) 2 precipitation. Transfection efficiency was normalized to the levels of growth hormone expressed from cotransfected plasmid containing the Rous sarcoma virus promoter directing human growth hormone gene expression (pRSV-hGH) (2 g for Mono Mac 6 cells and 0.25 g for CV-1 cells), and the data are given in relative light units (RLU) per nanogram of growth hormone. Growth hormone concentrations were measured by radioimmunoassaying (Nichols Institute, San Juan Capistrano, Calif.).
Expression and purification of recombinant proteins. A 100-ml volume of Escherichia coli DH5␣ cells containing GST fusion protein expression plasmids was cultured at 37ЊC for 1 h after 1:10 dilution of the cells. The production of GST fusion protein was induced by culturing cells at 32ЊC for 3 h in the presence of 1 mM isopropyl-␤-D-thiogalactopyranoside. GST fusion proteins were prepared as described elsewhere (60) . The quality and the quantity of GST fusion proteins were examined by Coomassie blue staining of sodium dodecyl sulfate (SDS) gels with bovine serum albumin as a standard. C/EBP␣, AML1B, and CBF␤ were in vitro translated from the plasmids pKS-C/EBP␣ (C/EBP␣ cDNA in the EcoRI and HindIII sites of pBluescript KS Ϫ ), pBS-AML1B (35) , and pKS-CBF␤5 (35) , respectively, with the TnT T7-coupled reticulocyte lysate system (Promega no. L4610) according to the manufacturer's protocols. Approximately 2 g of GST protein or GST fusion proteins immobilized on glutathione agarose beads was incubated with in vitro-translated 35 S-labeled proteins for 2 h in 500 l of interaction buffer (150 mM NaCl, 20 mM Tris [pH 7.5], 0.3% Nonidet P-40, 0.1 mM EDTA, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, and 1 g of leupeptin, pepstatin A, chymostatin, antipain, aprotinin, and trypsin inhibitor per ml) at 4ЊC with gentle rocking. The protein-GST beads were washed four times with the same buffer at 4ЊC. SDS-polyacrylamide gel electrophoresis was then used to analyze bound proteins.
RESULTS
C/EBP transcription factors interact with region IIA of the M-CSF receptor promoter. Previous studies have shown that transcriptional regulation is very important for tissue-specific expression of the M-CSF receptor in monocytic cells (20, 37, 52, 80) and that the region from bp Ϫ85 to ϩ71 of the human M-CSF receptor contains monocytic promoter activity (79) . This region can interact with transcription factors PU.1 and, AML1 and a monocyte-enriched factor, which we named Mono A, as shown in Fig. 1A (79) . Mono A specifically binds to region IIA (bp Ϫ88 to Ϫ73) of the M-CSF receptor. Transient transfections with region IIA-mutated promoter-luciferase gene constructs demonstrated that region IIA was critical for M-CSF receptor promoter activity (79) . Heterologous promoter studies showed that region II functions as a monocytespecific enhancer (79) . We compared the DNA sequence in region IIA with the binding region sequences of known transcription factors. The sequence TTTGGAAAT on the noncoding strand of the M-CSF receptor at bp Ϫ76 to Ϫ84 is similar to the sequence TTNNGNAAT, which is a consensus sequence C/EBP binding site (42) . To assay whether C/EBP family members could interact with the M-CSF receptor promoter region IIA, recombinant C/EBP␣, C/EBP␤, and C/EBP␦ were prepared from COS-7 cells transiently transfected with expression vectors for these C/EBP proteins. These proteins were used in EMSA analysis with a 32 P-labeled, double-stranded region IIA oligonucleotide (bp Ϫ88 to Ϫ73) and an oligonucleotide containing the C/EBP binding site. As shown in Fig. 2 , nuclear extracts isolated from untransfected COS-7 cells did not interact with the M-CSF receptor promoter region IIA probe (lane 1) or the C/EBP binding site probe (data not shown). Recombinant C/EBP␣ (42 kDa), C/EBP␤ (34 kDa), and C/EBP␦ (33 kDa) bind to both the C/EBP oligonucleotide probe and the M-CSF receptor promoter region IIA.
Nuclear factor Mono A from monocyte nuclear extract which binds to region IIA of M-CSF receptor promoter is C/EBP. As shown in Fig. 2 , the DNA-protein complex formed with monocyte nuclear extract migrates at exactly the same position as recombinant C/EBP␣. This indicates that C/EBP could be the Mono A factor described in our previous study. To confirm that C/EBP is indeed the transcription factor bound to region IIA in monocytic cells, nuclear extracts from monocytic Mono Mac 6 cells and the region IIA probe were used in EMSA competition and supershift experiments as shown in Fig. 3 . The shifted protein-DNA complex can be inhibited specifically by unlabeled region IIA oligonucleotide or a C/EBP-binding oligonucleotide (Fig. 3, lanes 3 and 4) but not by a mutated C/EBP-binding oligonucleotide which no longer binds to C/EBP (Fig. 3, lane 5) . When an antiserum directed specifically against C/EBP␣ was present in the binding reaction mixture, the specific Mono A DNA-protein complex was abolished (Fig. 3, lane 6) . Antisera against C/EBP␤, C/EBP␦, or Oct-1 did not have any significant effect on the formation of the DNA-protein complex. These data indicate that monocytic transcription factor Mono A is C/EBP and that C/EBP␣ is the major form of the C/EBP in the binding complex. receptor promoter are in close proximity. There are only 3 bp between the two consensus binding sites (Fig. 1) . The C/EBP site mutation pM-CSF-R(mA) only abolishes C/EBP binding and does not affect the binding of AML1 to the M-CSF receptor promoter and vice versa (79) . Mutations at either the C/EBP-binding site or the AML1-binding site in the M-CSF receptor promoter significantly decrease promoter activity. The percentages of decrease resulting from mutation of either site are very similar (79) . Both single-site mutations decrease promoter activity specifically in monocytic cells to 13% of the wild-type promoter activity (79) . These data suggested that C/EBP and AML1 cooperate with each other. To further study this question, 5-and 10-bp insertion mutations between the C/EBP-and AML1-binding sites in the M-CSF receptor promoter were generated to change the orientation on the helix and the distance between these two factors (Fig. 1) . The promoter-luciferase constructs with insertion mutations were then used in transient transfection analysis as shown in Fig. 4 . In monocytic Mono Mac 6 cells, both 5-and 10-bp insertions reduced the activity of the M-CSF receptor promoter to 20% of the activity of the wild-type promoter. Thus, changing the relative orientation on the helix by insertion of 5 bp between the two factor-binding sites and changing the distance between the two factor-binding sites by insertion of 10 bp both significantly decreased promoter activity. These results suggested that C/EBP and AML1 cooperate to activate the M-CSF receptor promoter.
C/EBP physically interacts with AML1, but not the AML1 heterodimer partner CBF␤, in the absence of DNA. As noted previously, AML1 belongs to the CBF (PEBP2) family of transcription factors. CBF heterodimers consists of a DNA-binding ␣ subunit (CBF␣) and a non-DNA-binding ␤ subunit (CBF␤) (34, 48, 73) . Although the ␤ subunit does not bind to DNA, it facilitates the binding of the ␣/␤ complex to DNA. Since insertion of 5 or 10 bp between the two binding sites supported the idea that C/EBP and AML1 function in a cooperative manner (Fig. 4) , we further asked whether we could detect any physical interaction between these two proteins. We were unable to identify a more slowly migrating complex containing both C/EBP and CBF by EMSA using the M-CSF receptor promoter region II as a probe (data not shown). This indicates either that there is no interaction between the two factors or, alternatively, that the interaction is not stable enough to be detected by EMSA under our experimental conditions. To further study possible physical interactions, we performed in vitro binding experiments in which E. coli-expressed GST fusion proteins immobilized on glutathione agarose beads were incubated with in vitro-translated, 35 S-labeled proteins (Fig.  1B) . As shown in Fig. 5A , in vitro-translated AML1B can be specifically retained on agarose beads containing the fusion protein made from the AML1 heterodimer partner CBF␤ (GST-CBF␤) but not on glutathione agarose beads containing only GST. However, in vitro-translated C/EBP was not retained on GST-CBF␤-coated beads. This indicated that there is probably no direct interaction between CBF␤ and C/EBP. We then studied the interaction between C/EBP and AML1 using the GST C/EBP␣ basic region leucine zipper domain fusion protein (GST-C/EBPbZIP) and in vitro-translated AML1B as shown in Fig. 5B . AML1B can be specifically retained on agarose beads containing the GST-C/EBPbZIP fusion protein. To verify that the interaction is not due to nonspecific binding to agarose beads, the same volume of glutathione agarose beads either with the preparation used for GST fusion protein or without any treatment was used in the binding reaction mixture. As shown in lanes 4 and 5 of Fig. 5B , there is no significant interaction of naked beads with AML1B. A total of 16% of the 35 S-labeled AML1B added to the binding reaction mixture was bound to GST-bZIP. This result demonstrated a direct physical interaction between C/EBP and AML1B. As a positive control, GST-CBF␤ was used in a binding reaction mixture with GST-C/EBPbZIP and GST-CBF␤. This indicated that the physical interaction between C/EBP and AML1B is mediated at least in part through the Runt domain of the AML1B protein. This result is further confirmed by using the C-terminally deleted AML1B protein AML1B(N) (Fig. 1B) as shown in Fig.  5C . Transcriptional synergy between C/EBP and AML1B. C/EBPand AML1-binding site mutation analysis (Fig. 4) and proteinprotein interaction analysis (Fig. 5) both indicated that C/EBP and AML1 may function cooperatively to activate the M-CSF receptor promoter. To obtain further proof of this hypothesis, we performed cotransactivation experiments with monkey kidney CV-1 cells as shown in Fig. 6 . In CV-1 cells, basal M-CSF receptor promoter activity is about 3-to 10-fold above background compared with the promoterless construct. When C/EBP␣, AML1B, or CBF␤ was used alone in transactivation experiments with the M-CSF receptor promoter, there was no significant activation of promoter activity (Fig. 6 ). There was still no transactivation observed even after increases in the amount of expression vector to 5 or 10 g in the transfection experiments (data not shown). When AML1B and its heterodimer partner CBF␤ were used together, there was a 6-fold induction of M-CSF receptor promoter activity (Fig. 6 ). This indicates that CBF factors can activate the M-CSF receptor promoter without the presence of C/EBP. When C/EBP␣ and AML1B were used in the transactivation study in the absence of CBF␤, a 22-fold induction of M-CSF receptor promoter activity could be detected, demonstrating a synergistic effect between AML1B and C/EBP␣. In the absence of AML1B, C/EBP␣ and CBF␤ did not show any significant transactivation, in keeping with their lack of physical interactions (Fig. 5) . When all three factors, C/EBP␣, AML1B, and CBF␤, were used in the same transactivation experiment, M-CSF receptor promoter activity was induced by 90-fold. This demonstrated very strong transcriptional synergy of M-CSF receptor promoter activity in the presence of all three factors.
To assay whether transcriptional synergy with these factors is specifically mediated through the C/EBP-and AML1-binding sites, the M-CSF receptor promoter constructs with mutations which abolished C/EBP or AML1 binding or both were used in transactivation experiments in the presence of all three transcription factors. As shown in Fig. 7 , compared with the 55-fold induction of the wild-type promoter, the promoter lacking the C/EBP-binding site or both C/EBP-and AML1-binding sites showed only 2-fold induction with the expression of C/EBP␣, AML1B, and CBF␤. Again, loss of only the AML1-binding site caused a much lower (6-fold) induction than that by the wild type. These data demonstrate that the synergistic effect of 3) and C/EBP␣ (lanes 4 to 6) were incubated with E. coli-produced GST (lanes 2 and 5, respectively) or GST-CBF␤ (lanes 3 and 6, respectively) immobilized on glutathione agarose beads. (B) In vitro-translated, 35 S-labeled AML1B was loaded directly on the gel (2 l [lane 1]) or was incubated (5 l) with E. coli-produced GST (lane 2), GST-C/EBPbZIP (lane 3), or GST-CBF␤ immobilized on glutathione agarose beads (lane 6). As a control, the same volume of glutathione agarose beads as in the GST-C/ EBPbZIP binding reaction, treated in the same manner as GST fusion protein beads (lane 4), or glutathione agarose beads without any treatment (lane 5) was also used in a binding reaction with 35 S-labeled AML1B. (C) The in vitrotranslated, 35 S-labeled AML1 Runt homology domain, AML1(rhd), was incubated with E. coli-produced GST (lane 1), GST-C/EBPbZIP (lane 2), or GST-CBF␤ (lane 3) immobilized on glutathione agarose beads. Since AML1(rhd) is a small peptide and has only three methionines to label, the radiolabeled signal is very weak. To confirm this result, the in vitro-translated, 35 S-labeled AML1B amino-terminal peptide AML1B(N) (amino acids 1 to 206) was used to perform the same experiment as that with AML1(rhd) (lanes 4 to 6). Bound proteins were analyzed in SDS-polyacrylamide gels and were visualized by autoradiography. Apparent molecular size standards were bovine serum albumin (87 kDa), ovalbumin (46 kDa), carbonic anhydrase (30 kDa), and trypsin inhibitor (21.5 kDa). The structures of the GST-AML1B and GST-C/EBPbZIP proteins are shown in Fig. 1B.   FIG. 6 . C/EBP and AML1 synergistically activate the M-CSF receptor promoter. CV-1 cells were transfected by the Ca 3 (PO 4 ) 2 precipitation method with 10 g of the M-CSF receptor promoter luciferase construct pM-CSF-R-luc in the presence or absence of 1 g of the C/EBP␣, AML1B, and CBF␤ expression constructs pMSV-C/EBP␣, pCMV5-AML1B, and pCMV5-CBF␤, respectively, as indicated. Luciferase activities were normalized for transfection efficiency with the cotransfected growth hormone plasmid RSV-hGH. The data are the averages of three sets of experiments. The standard deviations of the means are indicated by the error bars. Fold increases in promoter activity are relative to that of the wild-type promoter in the absence of any additional transcription factors. these three transcription factors depends on intact DNA-binding sites.
There are multiple members of the C/EBP family, and all of these C/EBP contain very similar DNA-binding and dimerization basic leucine zipper domains (7, 77) . Although C/EBP␣ was the major form of C/EBP from monocytes which bound to the M-CSF receptor promoter (Fig. 2) , recombinant C/EBP␣, C/EBP␤, and C/EBP␦ can all bind to the M-CSF receptor promoter region IIA ( Fig. 2 and 3) . The protein interaction results in Fig. 5 had shown that a common bZIP region among C/EBP was critical for the AML1 and C/EBP interaction. To analyze the ability of other C/EBP to effect M-CSF receptor promoter activity, C/EBP␤ and C/EBP␦ were used in transactivation experiments in the presence of both AML1B and CBF␤. As shown in Fig. 8 , in addition to C/EBP␣, both C/EBP␤ and C/EBP␦ could transactivate the M-CSF receptor promoter.
DISCUSSION
In this study, we extended our previous work to identify C/EBP as a critical transcription factor for M-CSF receptor monocytic expression (previously named Mono A [79] ). In vitro protein-binding studies demonstrated a physical interaction between C/EBP and AML1, which bind to the M-CSF receptor promoter adjacent to each other. Transient cotransfection experiments showed very strong synergistic coactivation of the M-CSF receptor promoter by coexpressed C/EBP and AML1.
Here, we report that C/EBP␣ is critical for the activity of the M-CSF receptor promoter. Very recent studies from our group have shown that C/EBP␣ also plays a significant role in both G-CSF receptor and GM-CSF receptor ␣-chain promoter activities (19, 61) . Signal transduction from these three growth factors (M-CSF, G-CSF, and GM-CSF) inducing multipotential hematopoietic cells to differentiate toward the myeloid cell lineages depends on expression of their specific receptors. Therefore, C/EBP␣ could play a major role in regulation of myeloid cell development. This hypothesis can be tested by the analysis of myelopoiesis in C/EBP␣ knockout mice (72) .
An important question to be answered is which C/EBP protein is important for M-CSF receptor expression at different stages of macrophage development, from the first stages of myeloid cell commitment from multipotential progenitors to the late stages of macrophage maturation and activation. One possibility is that all three C/EBP proteins (C/EBP␣, C/EBP␤, and C/EBP␦) contribute to expression of the receptor, with the important variable being the pattern of C/EBP expression. The observed pattern of C/EBP expression during macrophage commitment and activation suggests that C/EBP␣ might be important for early expression in progenitors, but that later on C/EBP␤ and C/EBP␦ may be important during maturation and activation of macrophages (42, 56) . However, these studies did not compare absolute amounts of the different C/EBP in myeloid cells at different stages of differentiation (56) . In the myeloid cell lines used in our studies, we observed binding only by C/EBP␣. Additional studies with unstimulated and stimulated primary macrophages could help answer this question. A second hypothesis is that while all three C/EBP, C/EBP␣, C/EBP␤, and C/EBP␦, can bind to and activate the M-CSF receptor promoter ( Fig. 2 and 8 ), differences in affinities will also play an important role. Our studies suggest differences in the binding affinities of different recombinant C/EBP to the M-CSF receptor promoter site relative to a consensus C/EBP binding site oligonucleotide (Fig. 2) (7) . C/EBP␤ binding is relatively weaker than binding of C/EBP␣ and C/EBP␦. The different affinities might explain differences in efficiencies of the C/EBP in coactivation of the M-CSF receptor promoter shown in Fig. 8 . More definitive affinity studies are necessary to answer this question. Finally, the presence of other interacting proteins, such as AML1, may affect which C/EBP binds to and activates the promoter, although to date in our in vitro EMSA we have not been able to detect cooperativity in DNA binding of C/EBP and AML1 to their adjacent sites.
The identification of C/EBP as the Mono A factor further supports the idea that promoter specificity is mediated by a combination of transcription factors with different tissue specificities. We have previously shown that the activity and specificity of the M-CSF receptor promoter are mediated by a small DNA fragment containing binding sites for PU.1, AML1, and C/EBP (Fig. 1A) (79) . PU.1 is myeloid cell and B-cell specific (8, 26) , while AML1 is expressed in myeloid cells as well as lymphocytes (4, 31, 35a, 39, 54, 66, 79) . In the hematopoietic system, C/EBP␣ may be specifically expressed in myeloid cells (56) and may be preferentially expressed in macrophages (51a). Therefore, the combinatorial activities of PU.1, AML1, and C/EBP␣, all of which are specifically expressed in macrophages, may mediate the specificity of the M-CSF receptor promoter. In our previous studies, a DNA fragment containing both C/EBP-and AML1-binding sites, without the PU.1 site, can function as a monocyte-specific enhancer by using the heterologous basal TK promoter (79) . It may be that in the case of the M-CSF receptor, PU.1, which binds to TFIID (17, 74) , it is necessary to recruit the TATA-binding protein; however, this function can be substituted by the TATA box in the TK promoter, as was found in studies of the Fc␥R1b promoter (10) . These hypotheses can be tested by mutating and swapping the PU.1 site and the TATA box in the M-CSF receptor and TK promoters. It will be interesting to analyze whether a DNA fragment containing solely the PU.1-, AML1-, and VOL. 16, 1996 C/EBP AND AML1 SYNERGY ACTIVATES THE M-CSF RECEPTOR 1237 C/EBP-binding sites can direct gene expression in a monocytespecific manner in vivo in transgenic mouse studies. It has been previously suggested that AML1 acts to facilitate the action of other adjacent transcription factors, and it is interesting that the AML1 site is located between the C/EBP␣ and the PU.1 sites in the M-CSF receptor promoter (Fig. 1A) . Significantly, although the C/EBP site is critical for M-CSF receptor activity in transfection experiments (79) , C/EBP alone does not transactivate M-CSF receptor promoter activity (Fig.  6) . The adjacent factor AML1, along with CBF␤, can by itself activate the M-CSF receptor promoter by 6-fold, but the synergistic activation by C/EBP added to that by AML1 and CBF␤ is much greater (more than 60-fold). All C/EBP have highly similar bZIP domains (7, 77) , and AML1 interacts with the bZIP fragment of C/EBP (Fig. 5) , explaining why C/EBP␣, C/EBP␤, and C/EBP␦ all can synergistically activate the M-CSF receptor promoter with AML1 (Fig. 8) . Either the physical interaction between C/EBP and AML1 could either stabilize binding of both to the M-CSF receptor or their interaction might provide a surface for another transcription factor to bind and activate the M-CSF receptor promoter.
AML1 is a member of the CBF family of proteins, all of which have similar DNA-binding runt domains (3, 4, 31, 39, 49, 75) . Recent evidence obtained with antisera specific for CBF␣3 (AML2) and CBF␣1 (AML3) indicates that myeloid cells (and B cells) express both AML1 and CBF␣3, whereas the majority of the activity in T cells is composed of AML1 (35a). Since the Runt domain is directly involved in physical interaction with C/EBP (Fig. 5 ) and the Runt domain is the most conserved region among CBF proteins, other CBF members may substitute for AML1 in activation of the M-CSF receptor. Therefore, we tested this possibility by replacing AML1 with AML2 in the transactivation experiments. The results showed that AML2 can function like AML1 to transactivate the M-CSF receptor promoter.
Previous reports have indicated that AML1 can interact with Ets-1 and Myb (14, 18, 64, 78) . Our report is the first to describe physical interaction and cooperativity between AML1 and C/EBP. In contrast to the interaction between AML1 and Ets-1 (14, 64, 78) , this interaction is also mediated via the AML1 Runt domain (Fig. 5) . The data do not rule out the possibility that other regions of AML1B and C/EBP␣ in addition to the Runt and bZIP domains are involved in this physical interaction. The activation domains for both C/EBP and AML1 are outside the bZIP and Runt domains, respectively. However, these two domains are critical for the interaction of each factor with DNA and other transcription factors (13, 14, 29, 35, 43, 64) . We also studied the function of these two domains in activation of the M-CSF receptor promoter by expressing GST-AML1(rhd) or GST-C/EBPbZIP in transient transfection experiments in a manner similar to the experiments shown in Fig. 6 . The results indicate that neither AML1 (rhd) nor C/EBPbZIP can function as full-length AML1 or C/EBP for the activation of the M-CSF receptor promoter (data not shown). Further studies are necessary to elucidate which domains in AML1 and C/EBP are involved in the synergistic activation of M-CSF receptor expression.
